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 Abstract 
 
Lineage specific chimerism studies are commonly obtained at several time points after 
nonmyeloablative haematopoietic cell transplantation to assess the tempo and degree of 
engraftment, and to monitor graft rejection.  For patients who receive myeloablative 
transplants, the value of frequent chimerism analyses using sensitive molecular 
techniques is less certain.  In this study, a retrospective analysis was performed to 
assess the transplant outcome of 89 adult patients with acute lymphocytic leukaemia 
who had chimerism studies of unfractionated bone marrow cells or peripheral blood 
subsets performed approximately 80 days after transplantation. These patients received 
unmanipulated, myeloablative transplants using either HLA-identical or HLA-
mismatched, related or unrelated donor stem cells.   Incomplete donor engraftment was 
present only in the CD3+ peripheral blood T-cells in a small percentage of patients. 
There was no correlation of mixed chimerism with transplant outcome.  Routine “Day 80” 
chimerism studies in this group of patients who receive intensive, myeloablative 
conditioning regimens are not recommended. 
   
Introduction 
 
In nonmyeloablative haematopoietic cell transplantation (HCT), chimerism studies are 
routinely recommended to assess donor engraftment and to detect early signs of graft 
rejection.1,2  The role of serial chimerism studies, especially leukocyte subset studies, 
using sensitive molecular markers to monitor recipients of myeloablative HCT is less well 
defined.  A retrospective analysis of adult patients with acute lymphocytic leukaemia 
(ALL) who received myeloablative transplants at a single centre, using either related or 
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unrelated donors, was performed to determine if chimerism studies done approximately 
80 days after transplantation were predictive of transplant outcome.   
 
Materials and Methods 
 
Eighty-nine patients with ALL who were transplanted between January 1998 and 
December 2004 and had chimerism studies performed two to three months after 
transplantation were included in this study.  Informed consent was obtained from all 
patients, using forms approved by the Institutional Review Board of the Fred Hutchinson 
Cancer Research Center.   Seventy-eight patients had B-cell ALL, 8 had T-cell ALL, and 
3 had no phenotyping data.  At diagnosis, 30 patients had Philadelphia chromosome 
positive ALL, 19 had normal cytogenetics, 27 had other clonal cytogenetic abnormalities, 
and 13 had no cytogenetic  analyses available.  Median patient age was 33.5 years 
(range, 18.1 – 55.9 years).  Median duration of disease (time from date of diagnosis to 
date of transplant) was 8.4 months (range, 2.4 – 216.3 months).  Disease status at the 
time of transplant was based on marrow morphology:  39 patients were in 1st remission, 
29 were in >2nd remission and 21 were in relapse.  These patient characteristics are 
summarized in Table 1.  
 
All patients received a myeloablative conditioning regimen, which included 12.0 – 13.5 
Gy total body irradiation (TBI).  The source of stem cells was bone marrow (n=34), G-
CSF stimulated peripheral blood (n=54), or umbilical cord blood (n=1). None of the stem 
cell products were T-cell depleted.   Of 34 related donors, 32 were HLA-identical with the 
recipient and 2 were HLA-mismatched.  Of 55 unrelated donors, 37 were HLA-identical 
with the recipient and 18 were not.  HLA typing of patients and related donors included 
intermediate resolution typing for HLA-A, B, C and DQB1 genes and high-resolution 
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HLA-DRB1 typing.  HLA typing for patients undergoing an alternative donor search 
included high resolution typing for HLA-A, B, C and DRB1, and intermediate resolution 
typing for HLA-DQB1.3  Of the 19 patients who received adult, HLA-mismatched stem 
cells the degree of mismatching was as follows:  a single class I or class II antigen 
(n=12), a single class II allele (n=4) and a single class I plus a single class II allele (n=3).  
The only cord blood recipient was mismatched with the donor for both HLA-A antigens 
based on HLA-A, B, and DRB1 typing.  Fifty-two of the 89 recipients had donors of the 
same sex and 37 had opposite-sex donors.  Eighty-one of the 89 patients received 
cyclosporine and methotrexate for graft-vs.-host disease (GVHD) prophylaxis.4   Details 
of the conditioning regimens and GVHD prophylaxis are summarized in Table 2.   
 
Donor engraftment was initially assessed, per our standard practice, approximately 28 
days after transplantation.   Morphologic, conventional and molecular cytogenetic, and 
flow cytometric studies were performed on unfractionated bone marrow specimens at 
this time point.  
 
 At a median of 77 days (range, 65 - 113 days) after transplantation, the “Day 28” studies 
were repeated and chimerism analysis was also performed. Unfractionated bone marrow 
cells (BM) or peripheral blood (PB) sorted for CD3+ T-cells and CD33+ neutrophils were 
studied at this later time point.  Patients who had sex-mismatched donors had chimerism 
studies done by conventional cytogenetic analysis of metaphase chromosomes or by 
molecular cytogenetic techniques, i.e., fluorescence in situ hybridization (FISH) using X 
and Y chromosome-specific probes.5  Patients who had donors of the same sex had 
chimerism studies done by amplification and analysis  of variable number tandem repeat 
(VNTR) or short tandem repeat (STR) polymorphisms by DNA amplification.6  VNTR 
studies, performed routinely between 1998 and April, 2004, involved amplification of 
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individual VNTR loci with analysis on precast polyacrylamide gels with silver staining.7  
As of May 2004, same sex transplant pairs had chimerism studies performed by 
multiplex amplification of STR loci (PowerPlex 16, Promega, Madison, WI) with analysis 
by capillary electrophoresis (ABI 3130xl, Applied Biosystems, Foster City, CA).  
Sensitivity by both methods achieved at least 5% sensitivity as documented by external 
proficiency challenges.7,8  Depending on the relative size of the informative VNTR 
markers, sensitivity was as low as 0.1%, as assessed by internal mixing studies.  
Sensitivity of STR analysis routinely achieved 0.5% sensitivity as assessed by mixing 
studies. 
 
Disease-free survival probabilities were estimated using the Kaplan-Meier method.9 
 
Results 
 
The incidence of acute and chronic GVHD, survival, relapse, and causes of death are 
summarized in Table 2. 
 
Forty-seven patients had chimerism studies performed on unfractionated BM and 58 
patients had studies of fractionated PB samples.  (Twenty of the 89 patients had both 
BM and PB studies.)  Only two of the 47 patients who had chimerism studies of BM had 
<90% donor-derived cells (82.6% and 45%, respectively) at the time of analysis.  The 
patient with the lowest percent donor chimerism was known to be in relapse at the time 
the chimerism test was done.  Both of these patients died <4 months after transplant 
from relapsed ALL.  None of the 58 patients who had PB chimerism studies had <90% 
donor cells in the CD33+ neutrophil fraction.   There was a wider range in donor CD3+ T-
cell percentages as shown in Figure 1.   Eleven of the 58 patients had <90% donor CD3+ 
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T-cells, but none had <20% donor CD3+ T-cells, a level previously reported to be 
associated with graft loss.1  None of the patients in this analysis experienced subsequent 
graft rejection.  The actuarial probability of disease-free survival was not significantly 
different between the group of patients with <90% donor CD3+ T-cells and those with 
>90% donor CD3+ T-cells (62% vs. 48% at three years, respectively, p = 0.49).  
Similarly, there was no difference in the probability of relapse at three years between 
these two groups (38% vs. 40%, respectively). 
 
Of the 58 patients who had PB chimerism studies performed, the percentage of donor 
CD3+ T-cells did not correlate with the severity of acute GVHD, but only six of the 58 
patients developed mild (grade I) acute GVHD.  Similarly, stem cell source (BM versus 
PB), donor type (related versus unrelated), HLA-matching, and relapse after 
transplantation did not correlate with the degree of mixed chimerism in PB at the time of 
evaluation.  These observations, however, are based on a small number of patients in 
each subgroup who had mixed chimerism when tested. 
 
During the time period covered in this analysis, 23 additional adult ALL patients received 
myeloablative transplants, but did not have chimerism studies performed.  Twenty-one 
patients died early after transplantation (median day of death = day 29, range = 5-66 
days).  One patient had persistent disease after a syngeneic transplant and died on day 
204 after receiving a second transplant from an unrelated donor.  Two of the 23 patients 
relapsed, on days 19 and 47, with the relapse diagnosed by morphology of the 
peripheral smear or marrow, respectively.  None of the 22 patients had evidence of graft 
failure prior to death.  Only one of these 23 patients survived at least 80 days; this 
patient is alive in remission >7 years after HCT. 
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Discussion 
 
In patients undergoing nonmyeloablative or reduced-intensity HCT, chimerism analyses 
provide useful information regarding graft rejection and minimal residual disease.2,8  
Serial, quantitative chimerism studies have been recommended for children with ALL 
after allogeneic HCT to identify those patients at high risk of relapse.10  In general, 
analysis of PB cells is more useful than BM cells because lineage-specific chimerism 
can be determined.1  Before the advent of FISH and PCR-based studies, the degree of 
donor engraftment was assessed by conventional karyotype analyses for sex-
mismatched donor-recipient pairs, red blood cell phenotyping, or immunoglobulin 
isotypes.11   All of these techniques were associated with low sensitivity.  FISH analysis 
of sex chromosomes is more quantitative than conventional cytogenetics, while PCR-
based methodology (with VNTR or STR analyses) is not only a more sensitive 
technique, but also permits analysis of very small numbers of cells.  The sensitivity of 
VNTR and STR analyses by PCR methods is estimated at  1 – 5 %, but may be as low 
as 0.1% depending on the informative markers and the strength of amplification.6,7   The 
laboratory fees at this Center for one chimerism study using FISH or PCR-based 
technology range from $600 (without cell subset isolation) to $850 (with cell subset 
isolation by flow cytometry).   
 
The patient population in this retrospective analysis was fairly homogeneous, with all 
patients having a diagnosis of ALL,  being >18 years of age and receiving myeloablative, 
TBI-based conditioning regimens followed by infusion of allogeneic, unmanipulated stem 
cells.  GVHD prophylaxis was standardized with 91% of patients receiving cyclosporine 
and methotrexate.  Twenty-four percent of patients were in relapse at the time of 
transplantation, a factor which previously has been shown to be associated with a 
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significantly increased risk of post-transplant relapse.12  Two to three months after 
transplant a low frequency of incomplete donor chimerism was found.  In addition, 
lineage-specific (CD3+ and CD33+) peripheral blood chimerism studies were not 
predictive of transplant outcome, leading to the recommendation that these studies not 
be routinely obtained in this patient population.  This conclusion is in agreement with the 
recommendations for assessment of chimerism following myeloablative HCT for 
haematologic malignancies by the IBMTR/ABMTR.1 
 
In contrast, frequent PB chimerism studies have been recommended for children with 
ALL undergoing allogeneic transplantation to detect increasing mixed chimerism, 
allowing for early intervention with immunomodulatory therapy.10  The patient group in 
this study was more heterogeneous, with results grouped from several transplant 
centres.   Fifteen percent (25/163) of patients received chemotherapy-only preparative 
regimens and 41% (67/163) received T-cell depleted grafts.  Only one of the 163 
patients was in relapse at the time of transplant. 
 
The disparate conclusions about the role and timing of chimerism studies in the pediatric 
ALL study compared to our study illustrate the importance of defining the specific patient 
populations for whom chimerism studies are useful in monitoring transplant outcome.  
The value of chimerism studies for other subgroups of patients, including those who 
undergo myeloablative HCT using chemotherapy-only preparative regimens, patients 
who receive T-cell depleted grafts, and patients who have greater degrees of HLA 
disparity with their donors, e.g., haplo-identical transplant recipients, remains to be 
determined.   
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Figure 1   Variation in percentage of donor-derived CD3+ peripheral blood T-cells, based 
on VNTR or STR polymorphisms, or sex chromosome analysis by FISH.  
Table 1                Patient Characteristics 
Parameter Number1 
  
No. of patients 89 
  
ALL phenotype  
  B cell 78 
  T cell  8 
   Unknown  3 
  
Cytogenetics  
  Normal 19 
  Ph+2 30 
  Other clonal abnormalities3 27 
  No data 13 
  
Patient age, yrs  
  Median (range) 33.5 (18.1-55.9) 
  
Disease duration, mos4  
  Median (range) 8.4 (2.4-216.3) 
  
Pretransplant disease status5  
  1st remission 39 
  >2nd  remission 29 
  Relapse 21 
  
   
              1Number of patients, unless otherwise specified 
             2Ph+ includes patients with a t(9;22) only or t(9;22) plus additional clonal 
          abnormalities 
          3Includes unfavourable risk groups t(4;11), n=4; monosomy 7, n=1; 
trisomy 8, n=2.  There were no patients with t(8;14) or t(1;19).                    
Hyperdiploidy was present in 9 of these 27 patients. 
4Time from diagnosis of ALL to date of transplant 
5Defined by marrow morphology 
   
 
Table 2      Transplant regimens and outcome data 
Parameter Number1 
  
Preparative regimen  
  CY, 12.0 Gy TBI 51 
  CY, 13.2 Gy TBI 33 
  VP-16, 12-13.2 Gy TBI   4 
  Other   1 
  
Donor/recipient HLA compatibility  
  Related/matched 32 
  Related/mismatched   2 
  Unrelated/matched 37 
  Unrelated/mismatched 18 
  
Donor/recipient gender  
  M/M 34 
  M/F 15 
  F/F 18 
  F/M 22 
  
Stem cell source  
  Bone marrow 34 
  Peripheral blood 54 
  Umbilical cord blood   1 
  
GVHD prophylaxis  
  CSP + MTX 81 
  CSP + MMF   3 
  Sirolimus + tacrolimus + MTX   2 
  Tacrolimus, MMF   2 
  Other   1 
  
Acute GVHD  
  Grades 0 – I 12 
  Grades II – IV 77 
  
Day onset acute GVHD (grades I -I V)  
  Median (range) 19 (6 – 97) 
  
Chronic extensive GVHD 58 
  
Day onset chronic GVHD  
  Median (range) 139 (85 – 874) 
  
Graft rejection   0 
  
Day of relapse (n=41)  
  Median (range) 231 (75 – 1397) 
  
Survival  
  Patients alive 42 
  Patients dead 47 
  
Causes of death  
  Relapse 35 
  Infection 2 
  DAD/ARDS 1 
  Chronic GVHD +/- infection 7 
  Acute GVHD +/- infection 1 
  Other 1 
 
1Number of patients unless otherwise specified 
 Abbreviations:  CY  = cyclophosphamide 60 mg/kg once daily i.v. for 2 consecutive days 
(total dose 120 mg/kg); TBI = total body irradiation; VP-16 = etoposide; GVHD = graft-
vs.-host disease; CSP = cyclosporine; MTX = methotrexate; MMF = mycophenolate 
mofetil; DAD = diffuse alveolar damage; ARDS = acute respiratory distress syndrome 
